Javascript must be enabled to continue!
Survival between synchronous and non-synchronous multiple primary cutaneous melanomas—a SEER database analysis
View through CrossRef
Background
There is no criterion to distinguish synchronous and non-synchronous multiple primary cutaneous melanomas (MPMs). This study aimed to distinguish synchronous and non-synchronous MPMs and compare the survivals of them using the Surveillance, Epidemiology, and End Results database.
Methods
Synchronous and non-synchronous MPMs were distinguished by fitting the double log transformed distribution of the time interval between the first and second primary cutaneous melanomas (TIFtS) through a piecewise linear regression. The overall and melanoma-specific survivals were compared by the Kaplan–Meier method and Cox proportional hazard model through modeling the occurrence of synchronous MPMs as a time-dependent variable.
Results
The distribution of TIFtS was composed by three power-law distributions. According to its first inflection point, synchronous MPMs were defined as tumors that occurred within 2 months. The Kaplain–Meier plot revealed a significant inferior survival for synchronous MPMs than non-synchronous MPMs (
P
< 0.0001), and the occurrence of synchronous MPM was a risk factor for overall survival of cutaneous melanoma (CM) (hazard ratio: 2.213; (95% CI [2.087–2.346]);
P
< 0.0001).
Conclusions
This study provided data analysis evidences for using 2 months to distinguish synchronous MPMs and non-synchronous MPMs. Furthermore, the occurrence of synchronous MPM was a risk factor for prognosis of patients with CM.
Title: Survival between synchronous and non-synchronous multiple primary cutaneous melanomas—a SEER database analysis
Description:
Background
There is no criterion to distinguish synchronous and non-synchronous multiple primary cutaneous melanomas (MPMs).
This study aimed to distinguish synchronous and non-synchronous MPMs and compare the survivals of them using the Surveillance, Epidemiology, and End Results database.
Methods
Synchronous and non-synchronous MPMs were distinguished by fitting the double log transformed distribution of the time interval between the first and second primary cutaneous melanomas (TIFtS) through a piecewise linear regression.
The overall and melanoma-specific survivals were compared by the Kaplan–Meier method and Cox proportional hazard model through modeling the occurrence of synchronous MPMs as a time-dependent variable.
Results
The distribution of TIFtS was composed by three power-law distributions.
According to its first inflection point, synchronous MPMs were defined as tumors that occurred within 2 months.
The Kaplain–Meier plot revealed a significant inferior survival for synchronous MPMs than non-synchronous MPMs (
P
< 0.
0001), and the occurrence of synchronous MPM was a risk factor for overall survival of cutaneous melanoma (CM) (hazard ratio: 2.
213; (95% CI [2.
087–2.
346]);
P
< 0.
0001).
Conclusions
This study provided data analysis evidences for using 2 months to distinguish synchronous MPMs and non-synchronous MPMs.
Furthermore, the occurrence of synchronous MPM was a risk factor for prognosis of patients with CM.
Related Results
Preliminary Results on Clinicopathological and Immunohistochemical Features of Malignant Melanomas
Preliminary Results on Clinicopathological and Immunohistochemical Features of Malignant Melanomas
Abstract
Objective: To perform a retrospective clinico-pathological and immunohistochemical analysis of malignant melanomas. Methods: One-hundred sixty consecutiv...
Primary Cutaneous Rhabdomyosarcomatous Melanomas—A Report of Two Cases and Literature Review
Primary Cutaneous Rhabdomyosarcomatous Melanomas—A Report of Two Cases and Literature Review
Background and clinical significance: Cutaneous melanomas sometimes display unusual histopathological features, reminiscent of various other malignancies, either primary or metasta...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Background
Cutaneous involvement is very common in systemic lupus erythematosus. We describe the prevalence and spectrum of lupus-specific (cutaneous lupus eryt...
Primary Cutaneous Melanoma—Management in 2024
Primary Cutaneous Melanoma—Management in 2024
Background: Maximizing survival for patients with primary cutaneous melanomas (melanomas) depends on an early diagnosis and appropriate management. Several new drugs have been show...
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
Atypical BRAF and NRAS Mutations in Mucosal Melanoma
Primary mucosal melanomas represent a minority of melanomas, but have a significantly worse prognosis than cutaneous melanomas. A better characterization of the molecular pathogene...
Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation
Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation
A number of common driver mutations have been identified in melanoma, but other genetic or epigenetic aberrations are also likely to play a role in the pathogenesis of melanoma and...
Uveal melanoma: Long-term survival
Uveal melanoma: Long-term survival
Purpose
The long-term survival of uveal melanoma patients in the US is not known. We compared long-term survival estimates using relative survival, excess absolute risk (EAR), Kapl...

